With fibrotic disease being one of our areas of interest, it has been highly interesting to follow the news in the past six months or so around nintedanib. It is one of only two approved drugs for idiopathic pulmonary fibrosis, IPF. IPF continues to be a focus area for drug development. Even though its root […]
We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.
We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.
We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.
